ARA-290 — Apex Research Reference

01 / IDENTITY

Compound Profile

11

AMINO ACIDS

~1.3

kDa MW

SC

ROUTE

4–8h

HALF-LIFE

CLASSIFICATION

Helix B surface peptide (HBSP); tissue-protective receptor (TPR) agonist

MECHANISM

Binds the innate repair receptor (IRR / βcR heterodimer) — the tissue-protective arm of the EPO receptor. Does NOT stimulate erythropoiesis or raise hematocrit.

VIAL SIZE

10mg lyophilized powder

SEQUENCE

QEQLERALNSS (helix B loop fragment)

DEVELOPER

Araim Pharmaceuticals (Tarrytown, NY)

ALSO KNOWN AS

Cibinetide; HBSP; ARA290

02 / RESEARCH HISTORY

Development Timeline

2000–2004

Brines, Cerami & colleagues at The Rockefeller University discover that EPO has two distinct receptor systems: the classical EPOR homodimer (erythropoiesis) and a tissue-protective heterodimer (βcR + EPOR). Key insight: the tissue-protective effects can be separated from hematopoietic effects.

2008

Synthesis of ARA-290 (cibinetide) — an 11-amino-acid helix-B surface peptide derived from the EPO protein loop region responsible for tissue-protection signaling. Zero erythropoietic activity confirmed in preclinical models.

2010–2012

Phase I/II trials in Europe for diabetic peripheral neuropathy. Leiden University Medical Center (Netherlands) — Dr. Argyros and team document statistically significant corneal nerve fiber density (CNFD) regrowth and reduction in neuropathic pain scores.

2014

Diabetes (ADA journal) publishes randomized controlled trial: ARA-290 (4 mg/day SC × 28 days) vs. placebo in painful diabetic peripheral neuropathy. Primary endpoint met — corneal confocal microscopy confirmed new nerve fiber growth. Pain scores (VAS, NTSS-6) significantly improved.

2016–2019

Sarcoidosis trials at Maastricht University Medical Center. ARA-290 demonstrated reduction in small fiber neuropathy symptoms (burning pain, autonomic dysfunction) in sarcoidosis patients — a notoriously treatment-resistant condition. Received orphan drug designation (EU).

2020–2024

Expanded research into metabolic applications: improved insulin sensitivity in type 2 diabetes models, pancreatic beta-cell preservation, and inflammation resolution in metabolic syndrome. Post-COVID neuropathy research ongoing.

03 / BENEFITS

Primary Effects

01

Small Fiber Nerve Regeneration

ARA-290 is the only peptide with RCT-level evidence showing actual regrowth of small fiber nerve endings (corneal confocal microscopy as surrogate marker). In diabetic neuropathy trials, CNFD increased measurably after 28 days of 4mg/day SC dosing.

02

Neuropathic Pain Reduction

Significant improvement in NTSS-6 pain scores, burning sensation, and autonomic neuropathy symptoms (impaired sweating, orthostatic intolerance). Works through resolution of neuroinflammation rather than pain masking.

03

Systemic Anti-Inflammatory Action

Activates anti-inflammatory pathways downstream of the IRR. Reduces TNF-α, IL-6, and IL-1β in inflammatory models. Promotes M2 macrophage polarization (tissue-repair phenotype). Does not suppress immune function — it resolves inflammation.

04

Insulin Sensitivity & Beta-Cell Protection

Preclinical and early clinical data suggest ARA-290 improves glucose metabolism independent of body weight changes. May preserve pancreatic beta-cell mass in inflammatory/autoimmune environments. Relevant for metabolic syndrome and early T2D.

05

Organ & Tissue Cytoprotection

Strong ischemia-reperfusion protection in kidney, heart, and CNS models. ARA-290 post-conditioning significantly reduces infarct size and preserves organ function after ischemic insult — without polycythemia risk of full EPO.

06

Mood & Cognitive Function

Secondary endpoints in sarcoidosis trials showed improved fatigue scores and mood. Neuroinflammation reduction likely mechanism. Anecdotally reported: improved cognitive clarity, reduced brain fog — particularly relevant in post-viral syndrome contexts.

04 / RECONSTITUTION

Preparation Protocol

// 10MG VIAL — STANDARD RECONSTITUTION

10,000 mcg ÷ 300 units BAC water = 33.3 mcg per unit

Add 3.0 mL (300 units) bacteriostatic water to 10mg lyophilized vial.

TARGET DOSE	UNITS TO DRAW	VOLUME	NOTE
LOW1 mg1,000 mcg	30 units	0.30 mL	Maintenance / first-time use
STANDARD2 mg2,000 mcg	60 units	0.60 mL	Clinical trial dose (most evidence)
HIGH4 mg4,000 mcg	120 units	1.20 mL	Neuropathy trials dose; maximum studied

Storage: Lyophilized powder — room temperature, away from light. Reconstituted: refrigerate (2–8°C), use within 30 days. Do not freeze reconstituted solution. Protect from direct sunlight.

05 / DOSING PROTOCOL

Administration Guide

PROTOCOL	DOSE	FREQUENCY	DURATION	CONTEXT
INTRO	1–2 mg SC	Daily	2–4 weeks	Assess tolerance; neuroprotection onset
CLINICAL	4 mg SC	Daily	4 weeks	RCT-validated for neuropathy
MAINTENANCE	2 mg SC	3–5×/week	Ongoing	Sustained neuroprotection, metabolic support
ACUTE	4 mg SC	Daily × 28 days	1 month pulse	Active neuropathic pain, post-injury nerve repair

Injection site: Subcutaneous — abdomen, outer thigh, or flank. Rotate sites. No food restriction required; timing relative to meals is not critical. Most users dose in the morning or post-workout.

Notable: Unlike EPO, ARA-290 causes NO increase in hematocrit, hemoglobin, or red blood cell mass. Zero risk of blood viscosity complications. Safe in cardiovascular patients.

06 / TIMING

Administration Timing

PREFERRED WINDOW

Morning (fasted or fed — no difference demonstrated). Some users prefer post-workout for combined tissue-repair signaling.

FOOD RESTRICTION

None — ARA-290 is not affected by fed/fasted state. Administer any time.

STACKING TIMING

Can be co-administered with BPC-157, TB-500, or other repair peptides. Complementary mechanisms — no competition at receptor level.

FREQUENCY NOTES

Daily dosing provides most consistent tissue-protective signaling. 5 on / 2 off acceptable for maintenance phases.

ONSET

Nerve regeneration markers (CNFD) improve over 4–8 weeks. Pain reduction often noticed within 1–2 weeks of consistent use.

PEAK PLASMA

~2–4 hours post SC injection. Active tissue levels persist 4–8 hours. Daily dosing maintains protective receptor activation.

07 / BIOMARKERS

Monitoring Panel

// NERVE HEALTH

MARKER	TEST	CLINICAL RANGE	OPTIMAL (ON ARA-290)
Corneal Nerve Fiber DensityCorneal Confocal Microscopy (CCM)	CCM imaging	CLIN>5 fibers/mm²	OPTIncreasing trend over 8 weeks
Intraepidermal Nerve Fiber DensitySkin Punch Biopsy	Pathology lab	CLINAge/sex dependent (lab ref)	OPTWithin normal range for age
NF-Light (Neurofilament Light)Serum NfL	Blood draw (Simoa assay)	CLIN<20 pg/mL (age-adjusted)	OPT<10 pg/mL

// INFLAMMATION MARKERS

MARKER	TEST	CLINICAL RANGE	OPTIMAL
High-Sensitivity CRPhs-CRP	Standard panel	CLIN<3.0 mg/L	OPT<0.5 mg/L
Interleukin-6IL-6	Cytokine panel	CLIN<7 pg/mL	OPT<2 pg/mL
TNF-AlphaTNF-α	Cytokine panel	CLIN<8.1 pg/mL	OPT<3 pg/mL

// METABOLIC & HEMATOLOGIC SAFETY

MARKER	TEST	CLINICAL RANGE	EXPECTED ON ARA-290
HematocritHCT	CBC	CLINM: 38–50% \| F: 35–45%	OPTNO CHANGE — confirms non-erythropoietic
Fasting GlucoseFBG	Fasting blood glucose	CLIN70–99 mg/dL	OPT70–85 mg/dL
HbA1cGlycated Hemoglobin	Standard lab	CLIN<5.7%	OPT<5.2%
HemoglobinHgb	CBC	CLINM: 13.5–17.5 \| F: 12–15.5 g/dL	OPTNo change from baseline

08 / CYCLE PROTOCOL

Recommended Cycle

4–12

WEEKS ACTIVE

5–7

DAYS PER WEEK

4–8

WEEKS OFF

Daily

FREQUENCY

Phase 1 (Weeks 1–4): 4 mg/day SC — acute neuroprotection and inflammation resolution. This matches the RCT-validated protocol. Expect pain reduction and early nerve fiber recovery signals.

Phase 2 (Weeks 5–12): 2–4 mg SC, 5×/week — maintenance. CNFD continues to improve. Metabolic markers stabilize. Autonomic symptoms (sweating, GI motility) often improve in this window.

Off Period: 4–8 weeks off. Nerve regeneration effects persist beyond the dosing period due to structural changes (actual new nerve fibers). Re-assess with corneal confocal or symptom scores before restarting.

Stacking: ARA-290 + BPC-157 is a powerful combination for nerve and tissue repair. Add SS-31 for mitochondrial support in chronic neuropathy cases. Compatible with GHK-Cu for combined anti-inflammatory + tissue remodeling.

Research Compound Notice: ARA-290 (cibinetide) has completed Phase II clinical trials in Europe for diabetic neuropathy and sarcoidosis. It has received orphan drug designation (EU) and shown an excellent safety profile across multiple RCTs. All references to dosing and protocols are for educational purposes. Not approved by FDA. Consult a qualified healthcare provider.